Essity, a leading global hygiene and health company, has received a 2021 Innovative Technology contract from Vizient, Inc., the largest member-driven healthcare performance improvement company in the United States, for its Cutimed Sorbact.
The contract was awarded based on the recommendations of health care experts serving on a Vizient member-led council who interacted with the product through the Vizient Innovative Technology Program. The council determined the technology had the potential to enhance clinical care, patient safety, health care worker safety, or improve business operations of health care organizations.
Cutimed Sorbact redefines infection management with a physical mode of action, helping to promote wound healing, and in some cases, helping to reduce the risk of generating resistant strains of bacteria. Hydrophobic bacteria and fungi are attracted to the Sorbact mesh, which is applied directly to the wound, and bound pathogens are removed with each dressing change with an average bacterial load reduction of up to 73.1% in critically colonized wounds. Sorbact binds and lifts away pathogens, rather than killing them, ensuring no endotoxins are released which, could impair recovery.
Amy Gray, RN, BSN, CWS, Clinical Manager, Essity, said: “This contract from Vizient demonstrates Essity’s commitment to leveraging innovative technology to close hard to heal wounds and dramatically improve the lives of patients. Cutimed Sorbact provides an effective alternative to silver-based dressings, providing improved outcomes for our customers.”
Debbie Archer, Director of Procurement and Vizient Innovative Technology Program, said: “Hospitals and providers are looking for innovations that offer unique benefits over other products available on the market today. Our member council determined this technology met the criteria to be awarded the Innovative Technology contract. Congratulations to Essity on receiving this status.”
